{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T11:06:34Z","timestamp":1749467194949,"version":"3.38.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,13]]},"DOI":"10.7759\/cureus.80522","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T20:50:40Z","timestamp":1741899040000},"source":"Crossref","is-referenced-by-count":1,"title":["Intra-arterial Bevacizumab in Adult Patients With Steroid-Refractory Cerebral Radiation Necrosis: An Observational Study of Clinical Indications and Outcomes"],"prefix":"10.7759","author":[{"given":"Lisa B","family":"Shields","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert  J","family":"Kadner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahan","family":"Ghiassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher T","family":"Shelburne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael  W","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shervin R","family":"Dashti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not085","article-title":"Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery","volume":"15","author":"Boothe D","year":"2013","unstructured":"Boothe D, Young R, Yamada Y, Prager A, Chan T, Beal K. Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery. Neuro Oncol. 2013, 15:1257-63. 10.1093\/neuonc\/not085","journal-title":"Neuro Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2936e","article-title":"Bevacizumab for the treatment of radiation-induced cerebral necrosis: a systematic review of the literature","volume":"9","author":"Delishaj D","year":"2017","unstructured":"Delishaj D, Ursino S, Pasqualetti F, Cristaudo A, Cosottini M, Fabrini MG, Paiar F. Bevacizumab for the treatment of radiation-induced cerebral necrosis: a systematic review of the literature. J Clin Med Res. 2017, 9:273-80. 10.14740\/jocmr2936e","journal-title":"J Clin Med Res"},{"key":"ref3","article-title":"Evaluation of outcomes in patients who received bevacizumab for the treatment of brain radionecrosis","volume":"13","author":"Below JA","year":"2023","unstructured":"Below JA, Khan A, Brahim A, Raez LE, Izquierdo P. Evaluation of outcomes in patients who received bevacizumab for the treatment of brain radionecrosis. J Hematol Oncol Pharm. 2023, 13:72-6.","journal-title":"J Hematol Oncol Pharm"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3171\/2014.9.PEDS14198","article-title":"Targeted intraarterial anti-VEGF therapy for medically refractory radiation necrosis in the brain","volume":"15","author":"Dashti SR","year":"2015","unstructured":"Dashti SR, Spalding A, Kadner RJ, Yao T, Kumar A, Sun DA, LaRocca R. Targeted intraarterial anti-VEGF therapy for medically refractory radiation necrosis in the brain. J Neurosurg Pediatr. 2015, 15:20-5. 10.3171\/2014.9.PEDS14198","journal-title":"J Neurosurg Pediatr"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3171\/2022.2.JNS212006","article-title":"Single low-dose targeted bevacizumab infusion in adult patients with steroid-refractory radiation necrosis of the brain: a phase II open-label prospective clinical trial","volume":"137","author":"Dashti SR","year":"2022","unstructured":"Dashti SR, Kadner RJ, Folley BS, et al.. Single low-dose targeted bevacizumab infusion in adult patients with steroid-refractory radiation necrosis of the brain: a phase II open-label prospective clinical trial. J Neurosurg. 2022, 137:1676-86. 10.3171\/2022.2.JNS212006","journal-title":"J Neurosurg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-2417","article-title":"Bevacizumab as a treatment for radiation necrosis following stereotactic radiosurgery for brain metastases: clinical and radiation dosimetric impacts","volume":"10","author":"Li J","year":"2021","unstructured":"Li J, He J, Cai L, et al.. Bevacizumab as a treatment for radiation necrosis following stereotactic radiosurgery for brain metastases: clinical and radiation dosimetric impacts. Ann Palliat Med. 2021, 10:2018-26. 10.21037\/apm-20-2417","journal-title":"Ann Palliat Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2218-676X.2014.07.05","article-title":"The management of brain necrosis as a result of SRS treatment for intra-cranial tumors","volume":"3","author":"Patel U","year":"2014","unstructured":"Patel U, Patel A, Cobb C, Benkers T, Vermeulen S. The management of brain necrosis as a result of SRS treatment for intra-cranial tumors. Trans Cancer Res. 2014, 3:373-82. 10.3978\/j.issn.2218-676X.2014.07.05","journal-title":"Trans Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02103-0","article-title":"Single-shot bevacizumab for cerebral radiation injury","volume":"21","author":"Voss M","year":"2021","unstructured":"Voss M, Wenger KJ, Fokas E, Forster MT, Steinbach JP, Ronellenfitsch MW. Single-shot bevacizumab for cerebral radiation injury. BMC Neurol. 2021, 21:77. 10.1186\/s12883-021-02103-0","journal-title":"BMC Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3340\/jkns.2022.0229","article-title":"Effect of bevacizumab treatment in cerebral radiation necrosis : investigation of response predictors in a single-center experience","volume":"66","author":"Lee SH","year":"2023","unstructured":"Lee SH, Choi JW, Kong DS, Seol HJ, Nam DH, Lee JI. Effect of bevacizumab treatment in cerebral radiation necrosis : investigation of response predictors in a single-center experience. J Korean Neurosurg Soc. 2023, 66:562-72. 10.3340\/jkns.2022.0229","journal-title":"J Korean Neurosurg Soc"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.12.061","article-title":"Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system","volume":"79","author":"Levin VA","year":"2011","unstructured":"Levin VA, Bidaut L, Hou P, et al.. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011, 79:1487-95. 10.1016\/j.ijrobp.2009.12.061","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0950-1","article-title":"Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues","volume":"18","author":"Zhuang H","year":"2019","unstructured":"Zhuang H, Shi S, Yuan Z, Chang JY. Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues. Mol Cancer. 2019, 18:21. 10.1186\/s12943-019-0950-1","journal-title":"Mol Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07889-3","article-title":"Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis","volume":"21","author":"Khan M","year":"2021","unstructured":"Khan M, Zhao Z, Arooj S, Liao G. Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis. BMC Cancer. 2021, 21:167. 10.1186\/s12885-021-07889-3","journal-title":"BMC Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.593449","article-title":"Bevacizumab treatment of radiation-induced brain necrosis: a systematic review","volume":"11","author":"Liao G","year":"2021","unstructured":"Liao G, Khan M, Zhao Z, Arooj S, Yan M, Li X. Bevacizumab treatment of radiation-induced brain necrosis: a systematic review. Front Oncol. 2021, 11:593449. 10.3389\/fonc.2021.593449","journal-title":"Front Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2020-000114","article-title":"Proof-of-concept single-arm trial of bevacizumab therapy for brain arteriovenous malformation","volume":"3","author":"Muster R","year":"2021","unstructured":"Muster R, Ko N, Smith W, et al.. Proof-of-concept single-arm trial of bevacizumab therapy for brain arteriovenous malformation. BMJ Neurol Open. 2021, 3:e000114. 10.1136\/bmjno-2020-000114","journal-title":"BMJ Neurol Open"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28222","article-title":"Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma","volume":"13","author":"Vaios EJ","year":"2022","unstructured":"Vaios EJ, Batich KA, Buckley AF, et al.. Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma. Oncotarget. 2022, 13:576-82. 10.18632\/oncotarget.28222","journal-title":"Oncotarget"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.10.010","article-title":"Effect of bevacizumab on radiation necrosis of the brain","volume":"67","author":"Gonzalez J","year":"2007","unstructured":"Gonzalez J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys. 2007, 67:323-6. 10.1016\/j.ijrobp.2006.10.010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117556","article-title":"Bevacizumab for stereotactic radiosurgery-induced radiation necrosis in patients with non-small cell lung cancer treated with immune check-point inhibitors","volume":"427","author":"Moore A","year":"2021","unstructured":"Moore A, Yust-Katz S, Icht O, et al.. Bevacizumab for stereotactic radiosurgery-induced radiation necrosis in patients with non-small cell lung cancer treated with immune check-point inhibitors. J Neurol Sci. 2021, 427:117556. 10.1016\/j.jns.2021.117556","journal-title":"J Neurol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad071.018","article-title":"Bevacizumab for symptomatic radiation necrosis in brain metastases: outcomes from a single-center retrospective analysis","volume":"5","author":"Roberto K","year":"2023","unstructured":"Roberto K, Tyono I, Soliman H, Sahgal A, Perry J, Lim-Fat MJ. Bevacizumab for symptomatic radiation necrosis in brain metastases: outcomes from a single-center retrospective analysis. Neurooncol Adv. 2023, 5:i5. 10.1093\/noajnl\/vdad071.018","journal-title":"Neurooncol Adv"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e31829c3139","article-title":"Treatment of cerebral radiation necrosis with bevacizumab: the Cleveland clinic experience","volume":"38","author":"Sadraei NH","year":"2015","unstructured":"Sadraei NH, Dahiya S, Chao ST, et al.. Treatment of cerebral radiation necrosis with bevacizumab: the Cleveland clinic experience. Am J Clin Oncol. 2015, 38:304-10. 10.1097\/COC.0b013e31829c3139","journal-title":"Am J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.1866","article-title":"Bevacizumab reverses cerebral radiation necrosis","volume":"26","author":"Wong ET","year":"2008","unstructured":"Wong ET, Huberman M, Lu XQ, Mahadevan A. Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol. 2008, 26:5649-50. 10.1200\/JCO.2008.19.1866","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/srep24364","article-title":"A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis","volume":"6","author":"Zhuang H","year":"2016","unstructured":"Zhuang H, Yuan X, Zheng Y, et al.. A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis. Sci Rep. 2016, 6:24364. 10.1038\/srep24364","journal-title":"Sci Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S223258","article-title":"Ultra-low-dose bevacizumab for cerebral radiation necrosis: a prospective phase II clinical study","volume":"12","author":"Zhuang H","year":"2019","unstructured":"Zhuang H, Zhuang H, Shi S, Wang Y. Ultra-low-dose bevacizumab for cerebral radiation necrosis: a prospective phase II clinical study. Onco Targets Ther. 2019, 12:8447-53. 10.2147\/OTT.S223258","journal-title":"Onco Targets Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-016-2874-5","article-title":"Stereotactic radiosurgery planning based on time-resolved CTA for arteriovenous malformation: a case report and review of the literature","volume":"158","author":"Turner RC","year":"2016","unstructured":"Turner RC, Lucke-Wold BP, Josiah D, Gonzalez J, Schmidt M, Tarabishy AR, Bhatia S. Stereotactic radiosurgery planning based on time-resolved CTA for arteriovenous malformation: a case report and review of the literature. Acta Neurochir (Wien). 2016, 158:1555-62. 10.1007\/s00701-016-2874-5","journal-title":"Acta Neurochir (Wien)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1159\/000513560","article-title":"Resolution of radiation-induced necrosis in arteriovenous malformation with bevacizumab: a case report and review of current literature","volume":"13","author":"Kwong F","year":"2021","unstructured":"Kwong F, Scarpelli DB, Barajas RF, Monaco D, Tanyi JA, McClelland S, Jaboin JJ. Resolution of radiation-induced necrosis in arteriovenous malformation with bevacizumab: a case report and review of current literature. Case Rep Neurol. 2021, 13:297-304. 10.1159\/000513560","journal-title":"Case Rep Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/str.48.suppl_1.tp445","article-title":"Bevacizumab therapy for brain arteriovenous malformations","volume":"48","author":"Cooke DL","year":"2017","unstructured":"Cooke DL, Kim H, Smith W, et al.. Bevacizumab therapy for brain arteriovenous malformations. Stroke. 2017, 48:445. 10.1161\/str.48.suppl_1.tp445","journal-title":"Stroke"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1159\/000357447","article-title":"Effectiveness of bevacizumab for radiation-induced cerebral necrosis in children","volume":"49","author":"Preuss M","year":"2013","unstructured":"Preuss M, Hirsch W, Hoffmann KT, et al.. Effectiveness of bevacizumab for radiation-induced cerebral necrosis in children. Pediatr Neurosurg. 2013, 49:81-5. 10.1159\/000357447","journal-title":"Pediatr Neurosurg"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1080\/02688697.2020.1742294","article-title":"Late recovery of stereotactic\u00a0radiosurgery induced perilesional edema of an arteriovenous malformation after bevacizumab treatment","volume":"35","author":"Uysal E","year":"2021","unstructured":"Uysal E, Ba\u015fkurt O, Avc\u0131 \u0130, Peker HO, \u00c7elik SE. Late recovery of stereotactic\u00a0radiosurgery induced perilesional edema of an arteriovenous malformation after bevacizumab treatment. Br J Neurosurg. 2021, 35:22-6. 10.1080\/02688697.2020.1742294","journal-title":"Br J Neurosurg"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3171\/2012.1.JNS111627","article-title":"Bevacizumab used for the treatment of severe, refractory perilesional edema due to an arteriovenous malformation treated with stereotactic radiosurgery","volume":"116","author":"Williams BJ","year":"2012","unstructured":"Williams BJ, Park DM, Sheehan JP. Bevacizumab used for the treatment of severe, refractory perilesional edema due to an arteriovenous malformation treated with stereotactic radiosurgery. J Neurosurg. 2012, 116:972-7. 10.3171\/2012.1.JNS111627","journal-title":"J Neurosurg"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/405735","article-title":"Reassessing the role of intra-arterial drug delivery for glioblastoma multiforme treatment","volume":"2015","author":"Ellis JA","year":"2015","unstructured":"Ellis JA, Banu M, Hossain SS, Singh-Moon R, Lavine SD, Bruce JN, Joshi S. Reassessing the role of intra-arterial drug delivery for glioblastoma multiforme treatment. J Drug Deliv. 2015, 2015:405735. 10.1155\/2015\/405735","journal-title":"J Drug Deliv"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/346786-intra-arterial-bevacizumab-in-adult-patients-with-steroid-refractory-cerebral-radiation-necrosis-an-observational-study-of-clinical-indications-and-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T20:50:43Z","timestamp":1741899043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/346786-intra-arterial-bevacizumab-in-adult-patients-with-steroid-refractory-cerebral-radiation-necrosis-an-observational-study-of-clinical-indications-and-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.80522","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}